UK Markets open in 6 hrs 41 mins

Senseonics Holdings, Inc. (SENS)

NYSE American - NYSE American Delayed price. Currency in USD
Add to watchlist
3.3300-0.0900 (-2.63%)
At close: 4:00PM EDT
3.3300 0.00 (0.00%)
After hours: 07:58PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close3.4200
Open3.4400
Bid3.3400 x 4000
Ask3.3500 x 3100
Day's range3.3300 - 3.4470
52-week range0.3500 - 5.5600
Volume5,352,984
Avg. volume10,325,650
Market cap1.425B
Beta (5Y monthly)0.53
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • Business Wire

    Senseonics Holdings, Inc. Schedules Third Quarter 2021 Earnings Release and Conference Call for November 9, 2021, at 4:30 p.m. Eastern Time

    GERMANTOWN, Md., October 26, 2021--Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its third quarter 2021 financial results after market close on Tuesday, November 9, 2021.

  • Business Wire

    Senseonics Announces Equity Grants To Employees Under Inducement Plan

    GERMANTOWN, Md., October 04, 2021--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced that it had made equity grants to new employees under its 2019 Inducement Plan (the "Plan") in accordance with NYSE American Company Guide Section 711(a).

  • Business Wire

    Senseonics Announces a Collaboration with the University Hospitals Accountable Care Organization (UHACO) in Cleveland, Ohio

    GERMANTOWN, Md., September 13, 2021--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, and Ascensia Diabetes Care, the makers of the CONTOUR® family of diabetes blood glucose monitoring devices and commercialization partner for Senseonics, have announced that the University Hospitals Accountable Care Organiz